Liminatus Pharma, Inc.
LIMN
$14.43
$1.6312.73%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | -- | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | -99.82% | ||||
| Operating Income | 99.82% | ||||
| Income Before Tax | 99.87% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 99.87% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 99.87% | ||||
| EBIT | 99.82% | ||||
| EBITDA | -- | ||||
| EPS Basic | 100.00% | ||||
| Normalized Basic EPS | 100.00% | ||||
| EPS Diluted | 100.00% | ||||
| Normalized Diluted EPS | 100.00% | ||||
| Average Basic Shares Outstanding | -76.82% | ||||
| Average Diluted Shares Outstanding | -76.82% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||